A 3-year-old girl from rural Maharashtra presents with recurrent episodes of hypoketotic hypoglycemia, hepatomegaly, and developmental delay. Plasma carnitine levels are low. Urine organic acid analysis shows elevated dicarboxylic acids. What is the most appropriate next step in management?

Explanation

## Clinical Context This child presents with the classic triad of **primary carnitine deficiency (systemic carnitine deficiency)**: - Hypoketotic hypoglycemia (impaired fatty acid oxidation) - Hepatomegaly with fatty infiltration - Low plasma carnitine levels - Elevated dicarboxylic acids (evidence of incomplete β-oxidation) ## Pathophysiology **Key Point:** Carnitine is essential for transport of long-chain fatty acids (>12 carbons) across the inner mitochondrial membrane via the carnitine palmitoyltransferase (CPT) system. Without adequate carnitine, β-oxidation is severely impaired, leading to: 1. Failure to generate ATP from fat metabolism 2. Accumulation of fatty acyl-CoA in mitochondria 3. Shunting to alternative pathways → dicarboxylic acid excretion 4. Hypoketotic hypoglycemia (ketones not produced despite low glucose) ## Management Algorithm ```mermaid flowchart TD A[Suspected Carnitine Deficiency]:::outcome --> B{Plasma carnitine low + dicarboxylic acids elevated?}:::decision B -->|Yes| C[Confirm with genetic testing for SLC22A5 mutation]:::action C --> D[Initiate dietary management]:::action D --> E[MCT diet + avoid long-chain fats]:::action D --> F[Frequent small feeds to prevent fasting]:::action E --> G[Oral L-carnitine supplementation]:::action G --> H[Genetic counseling for family]:::action H --> I[Regular monitoring: plasma carnitine, glucose, liver function]:::outcome ``` ## Why This Answer is Correct **High-Yield:** The definitive management of primary carnitine deficiency combines: 1. **Genetic confirmation** (SLC22A5 gene mutations) — establishes diagnosis and enables family screening 2. **Dietary modification** — MCT diet bypasses the need for CPT-mediated transport (MCTs enter mitochondria directly); avoidance of long-chain fats reduces the metabolic load 3. **Oral L-carnitine** — replaces the deficient substrate (100–400 mg/kg/day in divided doses) 4. **Genetic counseling** — autosomal recessive inheritance; siblings at 25% risk **Clinical Pearl:** MCT oil is metabolized via β-oxidation in the mitochondrial matrix without requiring carnitine; it is the cornerstone of dietary therapy and often allows normal growth and development when combined with carnitine replacement. ## Monitoring - Plasma carnitine levels (target >20 µmol/L) - Fasting blood glucose and lactate - Liver enzymes and ultrasound (regression of hepatomegaly expected within weeks) - Developmental milestones [cite:KD Tripathi 8e Ch 24]